All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Blogs » BioWorld Perspectives » A shot in the dark? ‘Flu’ Manchu-type fears of evil pharma, plus frets over strains and safety, keep too many away from vaccine

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Vaccines

A shot in the dark? ‘Flu’ Manchu-type fears of evil pharma, plus frets over strains and safety, keep too many away from vaccine

Oct. 7, 2014
By Randy Osborne
No Comments

blog flu pixBy now I’ve learned to keep my flu shot habit a secret.

Every year about this time, since I was 18 years old, I get vaccinated. But long ago I stopped telling people about it, so I don’t have to hear: “Oh, you know the flu vaccines are made of antifreeze [mercury, aluminum, formaldehyde], right?” or “That’s a crazy thing to do, because the shot itself can make you sick!” or – this one’s fairly new – “You don’t really need it if you’ve got a healthy immune system. Anyway flu shots cause Alzheimer’s [in the old] and autism [in the young].”

I avoid talking about flu shots as carefully as I avoid letting strangers know that my job has anything to do with the pharmaceutical industry. As soon as they find out, they want to argue with me about drug pricing. They make tedious jokes about Viagra, medical pot and these days, nervously, Ebola. They demand to know why “the industry” (it’s a single, uniform entity) is keeping “the cure” for cancer (they think there’s just one cure) a secret. Oh wait! They already know why!

So I’ve been getting the flu shot every year since the afternoon in 1973 when I came home after seeing “The Exorcist,” and collapsed on the floor in the fetal position.  Every muscle in my body ached, as if I had been beaten with telephone books. My skin was hot. I shivered.

 I thought I was possessed by something from hell. I thought I was going to die. Then the coughing started.

This was not the upset stomach that I’ve heard others describe as the “intestinal flu,” or the sniffles that more likely herald the onset of an annoying but relatively harmless cold. This was the real thing. I wanted never to encounter it again. So far, I haven’t.

Today, as the flu-bearing Orthomyxoviridae begin to microbe their insidious ways across the land for the seasonal onslaught, flu shot skeptics – some of them high caliber, like the Johns Hopkins scientist who spoke up last May – are making noise again, and the voice of opposing research is trying to be heard in the mainstream media. The Centers for Disease Control and prevention (CDC) bangs the same drum as always, adjusted for what’s believed to lie ahead.

As of mid-August, according to the CDC, seven flu vaccine makers were projecting that as many as 159 million doses will be available, with about 77 million of those made as quadrivalent shots, protecting against four strains. Of course, it’s a dice game annually as to whether the shots are properly made to protect against the flu varieties coming our way. But it’s a game worth the toss, I think.

So I’m getting in line again to fight the demon. Are you getting a flu shot this year? Consider this as an informal, private survey. I won’t tell anyone.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing